Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks.
Roberts JD, Shibata S, Spicer DV, McLeod HL, Tombes MB, Kyle B, Carroll M, Sheedy B, Collier MA, Pithavala YK, Paradiso LJ, Clendeninn NJ.
Roberts JD, et al. Among authors: collier ma.
Cancer Chemother Pharmacol. 2000;45(5):423-7. doi: 10.1007/s002800051012.
Cancer Chemother Pharmacol. 2000.
PMID: 10803927
Clinical Trial.